Please assess the completion status of the following clinical trial:

Trial Title: Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent~2. Verified diagnosis of PSC~3. PSC patients with or without IBD~4. Women of childbearing potential have to apply during the entire duration of the study a highly effective method of birth control.~Exclusion Criteria:~1. History or presence of other concomitant liver diseases~2. Treatment with UDCA within 8 weeks prior to baseline visit.~3. Child B/C liver cirrhosis~4. Total bilirubin \> 3.0 mg/dl at screening or baseline.~5. Any relevant systemic disease~6. TSH\>ULN at screening~7. any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder~8. Any active malignant disease~9. Known intolerance/hypersensitivity to study drug~10. Existing or intended pregnancy of brest feeding~11. Simultaneous participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: EXPERIMENTAL): norUDCA
- C (Type: EXPERIMENTAL): norUDCA
- placebo (Type: PLACEBO_COMPARATOR): Placebo
- A (Type: EXPERIMENTAL): norUDCA

Based on this trial design, predict the completion outcome and termination type (if applicable).